Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT02431845
Recruiting Not applicable

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

NCT02431845 · tracked via the Priya Life Science South Korea tracker
Sponsor
Severance Hospital
Phase
Not applicable
Started
2013-01-01
Last updated
2024-12-27

Condition(s) studied

Obsessive-Compulsive Disorder

Investigational drug(s) / intervention(s)

SSRIs →

SSRIs: usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents

Study summary

The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Eligibility

Sex
ALL
Min age
19 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. age 19\~ 70 2. OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV) 3. drug naive or drug free for more than 3 months Exclusion Criteria: 1. any neurological disorder 2. comorbid psychotic disorders 3. alcohol or other substance dependence within past 6 months 4. any evidences for brain diseases

Primary outcome measure(s)

  • Change from baseline in the Yale-Brown Obsessive-Compulsive Scale — baseline, 3 or 4 months, 6 months, 1 year
    rating scale for obsessive-compulsive symptom severity consisting of 10 items

Trial sites (1)

FacilityCityRegionStatus
Yonsei Univ. Health System Severance Hospital Seoul South Korea Recruiting

More Severance Hospital trials in South Korea

Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery Active, not recruiting
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02431845 on ClinicalTrials.gov ↗ ← All trials in South Korea